Drugs Made In America Acquisition DMIIR Cash Flow Statement (2025-2026)

NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT
Reported Financials

Drugs Made In America Acquisition Quarterly Cash Flow Statement

Periods 3 quarters
Latest Jun 2026

Drugs Made In America Acquisition cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 3 quarters of results from Sep 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2025 Dec2025 Jun2026
Operating Activities
Net Income -0.05M4.59M4.40M
Cash from Operations -0.69M-0.31M
Change in Working Capital
Change in Account Payables 0.00M0.09M
Change in Accured Expenses 0.08M
Misc.
Change in Cash 0.31M-0.31M
Free Cash Flow -0.69M-0.31M
Net Cash Flow -0.69M-0.31M